Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences in-process research and development (IPR&D) impairment charges ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations
Latest, Q2 2026
12,043
Period ended Jun 30, 2026
Change on a year earlier
+19,642.6%
61 in Q2 2025
History
36 quarters
Since Q1 2015
Sources
27
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences In-process research and development (IPR&D) impairment charges ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/iprd_impairment_exp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.